St John's wort-associated drug interactions: Short-term inhibition and long-term induction?

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 1, 2005, Pages 19-24

  Xie, Hong Guang ^a,b   Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANESTHETIC AGENT; BUSPIRONE; CHLORZOXAZONE; CYCLOSPORIN; DIGOXIN; FEXOFENADINE; HYPERICUM PERFORATUM EXTRACT; IMATINIB; INDINAVIR; IRINOTECAN; MEPHENYTOIN; METHADONE; MIDAZOLAM; NEVIRAPINE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PHENPROCOUMON; QUAZEPAM; RITONAVIR; ROSIGLITAZONE; SIMVASTATIN; TACROLIMUS; THEOPHYLLINE; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL; VORICONAZOLE; WARFARIN;

ALTERNATIVE MEDICINE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TRANSPORT; FLOWER; GENETIC TRANSCRIPTION; HERBAL MEDICINE; HYPERICUM PERFORATUM; INHIBITION KINETICS; NOTE; PRIORITY JOURNAL; TREATMENT FAILURE;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLOWERS; HYPERICUM; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PLANT EXTRACTS; TIME FACTORS;

EID: 21844471569     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.04.002     Document Type: Note

References (72)

1. J. Rengelshausen, M. Banfield, K.-D. Riedel, J. Burhenne, J. Weiss, T. Thomsen Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics Clin Pharmacol Ther 78 2005 25 33
2. A.H. Draves, S.E. Walker Analysis of the hypericin and pseudohypericin content of commercially available St John's wort preparations Can J Clin Pharmacol 10 2003 114 118
3. M. Karliova, U. Treichel, M. Malago, A. Frilling, G. Gerken, C.E. Broelsch Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation J Hepatol 33 2000 853 855
4. F. Ruschitzka, P.J. Meier, M. Turina, T.F. Lüscher, G. Noll Acute heart transplant rejection due to Saint John's wort Lancet 355 2000 548 549
5. G.W. Barone, B.J. Gurley, B.L. Ketel, M.L. Lightfoot, S.R. Abul-Ezz Drug interaction between St. John's wort and cyclosporine Ann Pharmacother 34 2000 1013 1016
6. S. Bauer, E. Stormer, A. Johne, H. Kruger, K. Budde, H.H. Neumayer Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients Br J Clin Pharmacol 55 2003 203 211
7. G.K. Dresser, U.I. Schwarz, G.R. Wilkinson, R.B. Kim Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects Clin Pharmacol Ther 73 2003 41 50
8. I. Mai, S. Bauer, E.S. Perloff, A. Johne, B. Uehleke, B. Frank Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction Clin Pharmacol Ther 76 2004 330 340
9. R. Bolley, C. Zulke, M. Kammerl, M. Fischereder, B.K. Kramer Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort [letter] Transplantation 73 2002 1009
10. I. Mai, E. Störmer, S. Bauer, H. Krüger, K. Budde, I. Roots Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients Nephrol Dial Transplant 18 2003 819 822
11. M.F. Hebert, J.M. Park, Y.L. Chen, S. Akhtar, A.M. Larson Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers J Clin Pharmacol 44 2004 89 94
12. S.C. Piscitelli, A.H. Burstein, D. Chaitt, R.M. Alfaro, J. Falloon Indinavir concentrations and St John's wort [published erratum appears in Lancet 2001;357:1210] Lancet 355 2000 547 548
13. M.D. Perloff, L.L. von Moltke, E. Stormer, R.I. Shader, D.J. Greenblatt Saint John's wort an in vitro analysis of P-glycoprotein induction due to extended exposure Br J Pharmacol 134 2001 1601 1608
14. M. Hennessy, D. Kelleher, J.P. Spiers, M. Barry, P. Kavanagh, D. Back St John's wort increases expression of P-glycoprotein implications for drug interactions Br J Clin Pharmacol 53 2002 75 82
15. J. Patel, B. Buddha, S. Dey, D. Pal, A.K. Mitra In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents changes in P-gp and CYP3A4 activity Am J Ther 11 2004 262 277
16. M.M. de Maat, R.M. Hoetelmans, R.A. Mathot, E.C. van Gorp, P.L. Meenhorst, J.W. Mulder Drug interaction between St John's wort and nevirapine AIDS 15 2001 420 421
17. A. Johne, J. Schmider, J. Brockmöller, A.M. Stadelmann, E. Stormer, S. Bauer Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum) J Clin Psychopharmacol 22 2002 46 54
18. N. Prost, L. Tichadou, F. Rodor, N. Nguyen, J.M. David, M.J. Jean-Pastor St. John's wort-venlafaxine interaction [in French] Presse Med 29 2000 1285 1286
19. J.S. Markowitz, J.L. Donovan, C.L. DeVane, R.M. Taylor, Y. Ruan, J.S. Wang Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme JAMA 290 2003 1500 1504
20. A. Kawaguchi, M. Ohmori, S. Tsuruoka, K. Nishiki, K. Harada, I. Miyamori Drug interaction between St John's wort and quazepam Br J Clin Pharmacol 58 2004 403 410
21. M. Dannawi Possible serotonin syndrome after combination of buspirone and St John's wort [letter] J Psychopharmacol 16 2002 401
22. Z.Q. Wang, C. Gorski, M.A. Hamman, S.M. Huang, L.J. Lesko, S.D. Hall The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity Clin Pharmacol Ther 70 2001 317 326
23. B.J. Gurley, S.F. Gardner, M.A. Hubbard, D.K. Williams, W.B. Gentry, Y. Cui Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans Clin Pharmacol Ther 72 2002 276 287
24. S.D. Hall, Z.Q. Wang, S.M. Huang, M.A. Hamman, N. Vasavada, A.Q. Adigun The interaction between St John's wort and an oral contraceptive Clin Pharmacol Ther 74 2003 525 535
25. S.F. Zhou, E. Chan, S.Q. Pan, M. Huang, E.J.D. Lee Pharmacokinetic interactions of drugs with St John's wort J Psychopharmacol 18 2004 262 276
26. R.J. Xie, L.H. Tan, E.C. Polasek, C. Hong, M. Teillol-Foo, T. Gordi CYP3A4 and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations J Clin Pharmacol 45 2005 352 356
27. D. Eich-Hochli, R. Oppliger, K.P. Golay, P. Baumann, C.B. Eap Methadone maintenance treatment and St. John's wort-a case report Pharmacopsychiatry 36 2003 35 37
28. L.-S. Wang, B. Zhu, A.M. El-Aty, G. Zhou, Z. Li, J. Wu The influence of St John's wort on CYP2C19 activity with respect to genotype J Clin Pharmacol 44 2004 577 581
29. S. Crowe, K. McKeating Delayed emergence and St. John's wort Anesthesiology 96 2002 1025 1027
30. R.H.J. Mathijssen, J. Verweij, P. de Bruijn, W.J. Loos, A. Sparreboom Effects of St. John's wort on irinotecan metabolism J Natl Cancer Inst 94 2002 1247 1249
31. M.K. Ma, H.L. McLeod Lessons learned from the irinotecan metabolic pathway Curr Med Chem 10 2003 41 49
32. R.F. Frye, S.M. Fitzgerald, T.F. Lagattuta, M.W. Hruska, M.J. Egorin Effect of St John's wort on imatinib mesylate pharmacokinetics Clin Pharmacol Ther 76; 2004 323 329
33. P. Smith The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate Pharmacotherapy 24 2004 1058-14
34. P.A. Murphy St. John's wort and oral contraceptives reasons for concern? J Midwifery Womens Health 47 2002 447 450
35. A. Pfrunder, M. Schiesser, S. Gerber, M. Haschke, J. Bitzer, J. Drewe Interaction of St John's wort with low-dose oral contraceptive therapy a randomized controlled trial Br J Clin Pharmacol 56 2003 683 690
36. U.I. Schwarz, B. Büschel, W. Kirch Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception Br J Clin Pharmacol 55 2003 112 113
37. X.M. Jiang, K.M. Williams, W.S. Liauw, A.J. Ammit, B.D. Roufogalis, C.C. Duke Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects [published erratum appears in Br J Clin Pharmacol 2004;58:102] Br J Clin Pharmacol 57 2004 592 599
38. A. Maurer, A. Johne, S. Bauer Interaction of St John's wort extract with phenprocoumon [abstract] Eur J Clin Pharmacol 55 1999 A22
39. A. Johne, J. Brockmöller, S. Bauer, A. Maurer, M. Langheinrich, I. Roots Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) Clin Pharmacol Ther 66 1999 338 345
40. D. Dürr, B. Stieger, G.A. Kullak-Ublick, K.M. Rentsch, H.C. Steinert, P.J. Meier St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 Clin Pharmacol Ther 68 2000 598 604
41. S.C. Mueller, B. Uehleke, H. Woehling, M. Petzsch, J. Majcherpeszynska, E.M. Hehl Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin Clin Pharmacol Ther 75 2004 546 557
42. Z.Q. Wang, M.A. Hamman, S.M. Huang, L.J. Lesko, S.D. Hall Effect of St John's wort on the pharmacokinetics of fexofenadine Clin Pharmacol Ther 71 2002 414 420
43. L.-S. Wang, G. Zhou, B. Zhu, J. Wu, J.G. Wang, A.M.A. El-Aty St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole Clin Pharmacol Ther 75 2004 191 197
44. C. Tannergren, H. Engman, L. Knutson, M. Hedeland, U. Bondesson, H. Lennernas St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism Clin Pharmacol Ther 75 2004 298 309
45. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harada Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin Clin Pharmacol Ther 70 2001 518 524
46. A. Nebel, B.J. Schneider, R.K. Baker, D.J. Kroll Potential metabolic interaction between St. John's wort and theophylline [letter] Ann Pharmacother 33 1999 502
47. C.S. Karyekar, N.D. Eddington, T.C. Dowling Effect of St. John's wort extract on intestinal expression of cytochrome P4501A2 studies in LS180 cells J Postgrad Med 48 2002 97 100
48. M. Wenk, L. Todesco, S. Krahenbuhl Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females Br J Clin Pharmacol 57 2004 495 499
49. M.W. Hruska, J.A. Cheong, T.Y. Langaee, R.F. Frye Effect of St. John's wort administration on CYP2C8 mediated rosiglitazone metabolism [abstract] Clin Pharmacol Ther 77 2005 P35
50. T. Morimoto, T. Kotegawa, K. Tsutsumi, Y. Ohtani, H. Imai, S. Nakano Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers J Clin Pharmacol 44 2004 95 101
51. Food and Drug Administration/Center for Drug Evaluation and Research Public Health Advisory. Available from: URL: http://www.fda.gov/cder/drug/ advisory/stjwort.htm. Accessed March 15, 2005.
52. M. Wurglics, K. Westerhoff, A. Kaunzinger, A. Wilke, A. Baumeister, J. Dressman Comparison of German St. John's wort products according to hyperforin and total hypericin content J Am Pharm Assoc 41 2001 560 566
53. Z.J. Wang, S.M. Lin, M.L. Hu Contents of hypericin and pseudohypericin in five commercial products of St John's wort (Hypericum perforatum) J Sci Food Agric 84 2004 395 397
54. H.U. Schulz, M. Schurer, D. Bassler, D. Weiser Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet Arzneimittelforschung 55 2005 15 22
55. C.C. Webre, S. Kressmann, G. Fricker, W.E. Muller Modulation of P-glycoprotein function by St John's wort extract and its major constituents Pharmacopsychiatry 37 2004 292 298
56. S.C. Mueller, J. Majcher-Peszynska, S. Klammt, B. Uehleke, W. Miekisch, G. Kundt Induction of CYP3A by St. John's wort depends on hyperforin dose [abstract] Clin Pharmacol Ther 77 2005 P36
57. R.E. Watkins, J.M. Maglich, L.B. Moore, G.B. Wisely, S.M. Noble, P.R. Davis-Searles 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin Biochemistry 42 2003 1430 1438
58. J.M. Wentworth, M. Agostini, J. Love, J.W. Schwabe, V.K.K. Chatterjee St John's wort, a herbal antidepressant, activates the steroid X receptor J Endocrinol 166 2000 R11 R16
59. L.B. Moore, B. Goodwin, S.A. Jones, G.B. Wisely, C.J. Serabjit-Singh, T.M. Willson St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor Proc Natl Acad Sci U S A 97 2000 7500 7502
60. Y. Chen, S.S. Ferguson, M. Negishi, J.A. Goldstein Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor J Pharmacol Exp Ther 308 2004 495 501
61. S. Krusekopf, I. Roots, U. Kleeberg Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43 Eur J Pharmacol 466 2003 7 12
62. B.J. Komoroski, S.M. Zhang, H.B. Cai, J.M. Hutzler, R. Frye, T.S. Tracy Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures Drug Metab Dispos 32 2004 512 518
63. Y.P. Chen, S.S. Ferguson, M. Negishi, J.A. Goldstein Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter Mol Pharmacol 64 2003 316 324
64. R.S. Obach Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression J Pharmacol Exp Ther 294 2000 88 95
65. L. Zou, M.R. Harkey, G.L. Henderson Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity Life Sci 71 2002 1579 1589
66. E.J. Wang, M. Barecki-Roach, W.W. Johnson Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin J Pharm Pharmacol 56 2004 123 128
67. N. He, X. Collins, Y. Huang, T. Edeki Herbal components inhibit P-gp mediated digoxin transport in transwell cultured Caco-2 cell model [abstract] Clin Pharmacol Ther 77 2005 P77
68. D.J. Greenblatt, L.L. von Moltke, E.S. Perloff, Y. Luo, J.S. Harmatz, E. Bedir Effect of ginkgo on CYP2C9 in vitro and in vivo studies [abstract] Clin Pharmacol Ther 77 2005 P48
69. C.A. Roby, G.D. Anderson, E. Kantor, D.A. Dryer, A.H. Burstein St John's wort effect on CYP3A4 activity Clin Pharmacol Ther 67 2000 451 457
70. C.A. Roby, D.A. Dryer, A.H. Burstein St. John's wort effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios J Clin Psychopharmacol 21 2001 530 532
71. J.S. Markowitz, C.L. DeVane, D.W. Boulton, S.W. Carson, Z. Nahas, S.C. Risch Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers Life Sci 66 2000 PL133 PL139
72. R. Hyland, B.C. Jones, D.A. Smith Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole Drug Metab Dispos 31 2003 540 547